Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
17.21 USD | +0.94% | +0.79% | -44.95% |
Apr. 30 | UBS Adjusts ACADIA Pharmaceuticals' Price Target to $27 From $33, Keeps Buy Rating | MT |
Apr. 23 | Neuren Pharmaceuticals' Medication Secures Priority Review from Health Canada | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-44.95% | 2.82B | |
+22.01% | 47.9B | |
+46.56% | 41.42B | |
-2.15% | 40.7B | |
-6.20% | 28.92B | |
+10.33% | 25.55B | |
-21.14% | 19.27B | |
-2.07% | 12.15B | |
+31.68% | 12.14B | |
-0.33% | 11.99B |
- Stock Market
- Equities
- ACAD Stock
- News ACADIA Pharmaceuticals Inc.
- RBC Boosts Price Target on ACADIA Pharmaceuticals to $36 From $33, Keeps Outperform Rating